This review focuses on the literature published during the 13 months from December 2016 to December 2017 that is of interest to anesthesiologists taking care of children and adults with congenital heart disease. Five themes are addressed during this time period and 100 peer-reviewed articles are discussed.
Introduction
This article follows similar reviews by the authors for the years 2013 to 2016. [1] [2] [3] [4] The 2017 literature was searched using the following terms: congenital heart disease (CHD), adults, children, anesthesia, cardiac surgery, cardiopulmonary bypass, pulmonary hypertension, and cardiology in the US National Library of Medicine PubMed database. Five themes were identified: anesthetic agent neurotoxicity and neurological outcomes, imaging in congenital heart disease, congenital cardiac registries, blood products, and adult congenital heart disease. The discussions in each of these areas are by no means exhaustive, but the themes selected highlight recent research that may be of interest to anesthesiologists caring for children and adults with CHD. A few references are outside of the 13-month search window but were included as they clarify the specific research in the themes selected.
Anesthetic Agent Neurotoxicity and Neurological Outcomes
On December 14, 2016, the US Food and Drug Administration (FDA) issued a warning that repeated or lengthy use of general anesthetic and sedation drugs during surgeries or procedures in children younger than 3 years of age or in pregnant women during their third trimester may affect the development of children's brains. 5 In April 2017, the FDA updated the warning to explain that consistent with animal studies and recent human studies, a single, relatively short exposure to general anesthetic and sedation medications in infants or toddlers is unlikely to have negative effects on behavior or learning. 6 The FDA requires this information to be described on the labels of anesthetic agents. Additionally, these medication labels warn about pregnancy and pediatric use due to studies in young animals and pregnant animals that showed exposure to general anesthetic and sedation drugs for more than 3 hours can cause widespread loss of nerve cells in the developing brain. Additional neuromodulatory changes that occur result in long-term negative effects on the animals' behavior and learning. 7, 8 The FDA warning surprised many in the pediatric anesthesia community and resulted in multiple editorial comments during the last year. Concerns were raised that the FDA warnings may delay necessary surgical and diagnostic procedures requiring anesthesia, especially those expected to last longer than 3 hours, which may result in adverse outcomes for patients. Additional concerns have been raised about the impact on graduate medical education and the future of surgical and anesthetic training in the care of young children. 9, 10 Some authors cautioned that extrapolation of animal data to human medical care is still fraught with potential error and that it might be premature to include neurocognitive complications as part of the standard anesthetic consent for infants and young children. 11 Another editorial advised that all of the scientific evidence should be considered collectively rather than only the first sentence of the FDA warning. 12 Clearly, further prospective clinical data are needed, and the anesthesia community patiently awaits the results of 5 prospective clinical trials currently underway. Summaries of these studies were presented at the Fifth Pediatric Anesthesia Neurodevelopmental Assessment Symposium at the end of 2016. These studies include the GAS (General Anesthesia compared to Spinal Anesthesia) Trial, the T-Rex (Toxicity of Remifentanil-Dexmedetomidine) Trial, the MASK (Mayo Anesthesia Safety in Kids) Study, the UCSF (University of California San Francisco) Human Cohort Study, and the CUMC (Columbia University Medical Center) Neonatal MRI Study. These studies were recently well summarized, and once completed, these studies will go a long way to delineating the ongoing question of whether early anesthesia exposure in children is associated with subsequent learning difficulties. 13 During the past year, 4 large retrospective clinical studies on anesthetic exposure early in life were published. Analysis of 2 174 073 Swedish children born between 1973 and 1993 revealed 33 514 children with a single surgery with anesthesia exposure before 4 years of age and no further hospitalizations for analysis. In this study, reassuringly, there was a low overall difference in academic performance after childhood exposure to anesthesia when mean school grades at age 16 years in all children, and IQ testing in 18-year-old males during military conscription, were compared with 159 619 matched control children who had not received anesthesia. The academic grades were 0.41% lower at age 16 years and IQ testing was 0.97% lower at age 18 years. 14 A second large retrospective study from Ontario looked at 28 366 children exposed to general anesthesia compared with 55 910 unexposed controls. Study subjects were matched by gestational age at birth, maternal age, geographical location, and year of birth. Reassuringly in this study, 5500 children who were less than 2 years of age and who had been exposed to multiple anesthetics had no change in early developmental index testing. 15 A third large retrospective study from Manitoba compared 4480 children exposed to surgery and anesthesia before 4 years of age and 12 000 matched unexposed control children. In this study, the authors could not confirm an association between multiple general anesthesia exposure and increased risk of neurocognitive impairment. 16 A study from Western Australia looked at language fundamentals in 1622 children with available test scores who had been exposed to volatile anesthetics 10 years earlier, before the age of 3 years. The results of this study were not quite as favorable as the preceding 3 studies. Children with volatile anesthetic exposure less than 35 minutes did not differ from unexposed children regarding language development; however, children with exposure more than 35 minutes had lower total and expressive language scores. The authors do point out the limitations of a retrospective study and that their findings are only an association and could be due to other patient comorbidities. 17 On reviewing cardiac surgical neurological outcome studies, a recent study questions the prevailing view that surgery for hypoplastic left heart syndrome (HLHS) in the neonatal period with cardiopulmonary bypass (CPB) is associated with impaired neurodevelopment. This study found no difference in neurodevelopment analysis at preschool age in a cohort of 95 single ventricle patients, of which 69 had undergone the Norwood procedure during the neonatal period compared with 26 patients who had undergone their first non-Norwood surgical palliation (BT shunt, PA banding, etc) later in life. Interestingly in this study, neurodevelopmental outcome of preschool-aged Fontan patients was in the normal range. Limitations of this study include the relatively small sample size, and without cerebral magnetic resonance imaging (MRI) data, no association between neurodevelopmental outcome and brain injury could be assessed. 18 Type of cardiac lesion does seem to affect brain growth following neonatal cardiac surgery. A recent study of fullterm neonates compared brain MRI in 30 HLHS patients to 49 children with transposition of the great arteries (TGA). Subjects underwent presurgical and postoperative brain MRI within 1 month of surgery. Patients with HLHS had more stroke-related postoperative brain injury compared with TGA patients (55.6% vs 30.4%, P = .03). Patients with moderate-severe white matter injury had a slower rate of brain growth compared with those with no injury. Subjects with TGA had a greater rate of brain growth postoperatively compared with HLHS subjects. 19 Another study looked at brain MRI volumes 1 year out following cardiac surgery in 48 biventricular cardiac repair patients. These patients included TGA, tetralogy of Fallot, ventricular septal defects, and complete common atrioventricular canal defects operated on before 9 months of age. These subjects were compared with 13 control patients without CHD. Compared with control patients, infants with CHD had 54 mL less total brain volume (P = .009), 40 mL less cerebral white matter volume (P < .001), and 1.2 mL less brainstem volumes (P = .003). These changes in brain volumes in biventricular repair CHD patients were found to correlate with lower scores in communicative language development. 20 The implications of this study are the importance of language development surveillance in patients post cardiac surgery during infancy and the timely referral for interventions to improve language development if communication problems are observed.
There is continued research into studying serum neuronal biomarkers to identify potential brain injury during the perioperative period. One such biomarker is glial fibrillary acidic protein (GFAP), released in proportion to cell death. Although it has been studied since 1969, more recently it has come to prominence in studies related to brain trauma and CPB. 21 GFAP was recently studied in 69 children with CHD undergoing biventricular repair on CPB. Interestingly, the degree of hypothermia in this cohort of patients, rather than the duration of hypothermia, was associated with greater release of GFAP. There was no long-term neurological testing done in these patients, and the authors make the point that the clinical significance of GFAP in patients with CHD undergoing surgery on CPB with hypothermia is still not known, and that further studies will be needed to detect any GFAP predicted neurodevelopmental abnormalities. 22 Serum neuron-specific enolase and s100B, 2 other biomarkers that are released in increasing concentration proportional to a neurologic injury, have also recently been studied. Both biomarkers were shown to rise after CPB surgery in 18 neonates with CHD. Interestingly, s100B was positively correlated with the length of circulatory arrest time and negatively correlated with age at the time of surgery. The authors note that further studies are needed to see if there might be a benefit in waiting a longer period of time from the time of birth to surgery in neonates undergoing CHD repair on CPB. Additionally, the authors note further long-term studies are needed to assess neurodevelopmental outcomes after neonatal cardiac surgery to see if there is any prognostic utility of these biomarkers to predict clinical outcomes. 23 Aly and colleagues took a novel approach and used markers readily available to clinicians. They undertook a single-center, prospective clinical trial in 75 neonates undergoing cardiac surgery during the neonatal period. They utilized the cerebral tissue oxygenation index (cTOI) measured by near-infrared spectroscopy together with blood lactate levels and inotropic scores to predict neurodevelopmental outcomes (NDO) assessed by the Bayley Scales of Infant Development at 6, 15, and 21 months. 24 Median age at the time of surgery was 5 days, with a median weight of 3.5 kg. Forty patients had a single ventricle and 38 of these patients underwent a Norwood procedure. Thirty-five patients had 2 ventricles. Importantly, decreased cTOI in combination with blood lactate concentration at 60 minutes off CPB and 24 hours postoperatively were associated with mortality and adverse NDO. A cTOI <58% combined with a serum lactate level greater than 7.4 mmol/L at 24 hours postoperatively achieved a sensitivity of 95% in predicting a poor NDO. 24 The studies described above, together with the December 2016 and April 2017 FDA warnings, are very relevant to practitioners taking care of children with CHD. Thoughtful discussions are already occurring with many of our medical colleagues in cardiology, intensive care, radiology, and cardiac surgery when multiple procedures are being anticipated under one lengthy general anesthetic in children with CHD. There is a continued need for us to be informed about current research in the field of anesthetic agent neurotoxicity and neurodevelopmental outcomes following cardiac surgery so that we are prepared for in-depth discussions with medical colleagues and families, assessing the risks and benefits very carefully before undertaking any anesthetic and surgical encounters in young children. 12, 25 
Imaging in Congenital Heart Disease
No one imaging technology is perfect and able to deliver all the information needed in studying patients with CHD to inform on surgical decisions and long-term management. Multiple imaging modalities are required including cardiac catheterization. Cardiac catheterization is generally considered safe; however, it is not without risk, and in some cases the risk of complications may be as high as 24%. 26 The National Cardiovascular Data Registry, IMPACT (Improving Pediatric and Adult Congenital Treatment), is the largest clinical registry of patients undergoing diagnostic and interventional catheterization procedures. From January 2011 through March 2014, 39 725 catheterization procedures were performed at 74 US centers. Overall, a major adverse event occurred in 2832 (7.1%) of patients. Neonates were more likely to experience an adverse event (22.2% compared with 4.3% of children and 5.3% of adults). Single ventricle patients were more likely to experience an adverse event than biventricular patients (10.3% vs 6.4%). Other factors that play a role in determining risk include procedural type, coagulation disorder, renal insufficiency, genetic disorder, chronic lung disease, diabetes mellitus, hepatic disease, seizure disorder, sickle cell disease, and a history of stroke. 27 The importance of the evolution of transcatheter therapies in CHD cannot be overemphasized and has recently been well reviewed. 28 MRI is becoming more advanced in assessing anatomical structure and myocardial function and cardiac shunt fraction burden in pediatric patients with CHD. 29 However, it is not without risk and cardiac MRI in children usually requires a lengthy general anesthetic with endotracheal intubation and multiple breath holds to acquire excellent images. 30 A very helpful adjunct in specific circumstances to cardiac MRI is computed tomography (CT) used to acquire high spatial resolution, multiplanar reconstructive capabilities in a very short space of time. This modality has a particularly advantage in small children when images of the intrathoracic arteries, including coronary arteries and the airway in relation to the great vessels, are required to inform surgical decision making. 31 There have been dramatic improvements in CT technology. Radiation doses are nearly 50% to 60% less than they were a few years ago because prefilters and collimators are now able to filter out low-energy radiation that does not contribute to image quality. Faster scanning is possible with the use of dual source X-ray tube scanners resulting in a 1-second thoracic image and 5-second whole body image acquisition being possible with far less sedation needed for children. 32 These powerful imaging modalities are being transformed with the emerging technology of 3D printed models to accurately replicate complex cardiac anatomy. In a recent prospective study of 40 CHD patients ranging from 1 month to 34 years of age, at 10 international centers, consideration of a 3D printed model reconstruction acquired from MRI and CT imaging helped redefine the surgical approach in 19 of 40 cases. In 2 cases, initially assessed by MRI and CT imaging only, a biventricular repair was thought to be not possible. However, on study of the 3D printed model, a biventricular repair was planned and both cases were successful. Limitations of 3D printing include the inability to assess dynamic valve morphology and changes in myocardial geometry that occur during the cardiac cycle.
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Congenital Cardiac Registries
The Society of Thoracic Surgeons (STS) National Database was established in 1989 to record surgical outcome data for quality improvement and patient safety initiatives. The challenging component in the care of children with CHD is that all centers strive for standardized outcomes, but with individualized patient-specific care as the primary goal. However, when these individualized patient characteristics and outcomes from all registered centers are analyzed, what is then hoped for is a generalized decrease in the unnecessary variability in medical care that negatively affects patient outcomes. This unique STS database allows individual centers to compare and benchmark their own clinical outcomes to the national averages for specific congenital heart lesions. Additionally, comparative data analysis helps influence important goals such as center transparency and public reporting in congenital heart surgery. This greater transparency will, for example, ultimately allow families to navigate the informed decision-making process even before birth, so that they can make the best choice for themselves and their child as to which center they would prefer their child to visit to undergo cardiac surgery. 34 During 2017, an excellent comprehensive review describing the anesthetic component of this STS database for children with CHD was published. 35 The Congenital Cardiac Anesthesia Society has supported the STS multi-institutional database. Centers have been able to enter anesthetic-related data into this registry since 2005. In the spring of 2017, the current national aggregate outcomes from the STS database, for almost 400 000 congenital heart surgeries, was published. This is an important report, as it allows the overall aggregate mortality to be calculated including the interquartile range among all the registered surgical programs for 10 benchmark cardiac operations performed from July 2012 to June 2016. The mortality results from this analysis were the following: off-bypass coarctation of the aorta repair, 1.3% (0.0% to 1.8%); ventricular septal defect repair, 0.6% (0.0% to 0.9%); tetralogy of Fallot repair, 1.1% (0.0% to 1.4%); complete atrioventricular canal repair, 3.0% (0.0% to 4.7%); arterial switch operation, 2.7% (0.0% to 4.1%); arterial switch operation and ventricular septal defect repair, 5.3% (0.0% to 6.7%); Glenn/hemi-Fontan, 2.5% (0.0% to 4.5%); Fontan operation, 1.2% (0.0% to 1.2%); truncus arteriosus repair, 9.4% (0.0% to 16.7%); and the Norwood procedure, 15.7% (8.9% to 25%). 36 The STS database report is important as it strives to take into consideration all the risk factors associated with CHD surgery. For example, other factors rather than just the diagnosis were considered. The factors including the age and weight of the patient, any prior cardiothoracic surgery, any noncardiac congenital anatomic abnormality, any chromosomal abnormality or syndrome, and prematurity are taken into account. Additionally, preoperative risk factors such as mechanical circulatory support, shock, mechanical ventilation for cardiorespiratory failure, renal dysfunction or failure requiring dialysis, and preoperative neurological deficit are now included in the risk assessment.
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Bleeding and Thrombosis
Just as there is a spectrum of CHD, there is a spectrum of coagulation disturbances, from bleeding to thromboembolism. To further complicate matters, the coagulation profile is different between adults and neonates. Thrombosis is a relatively rare occurrence in childhood. In the children's hospitals acquired thrombosis (CHAT) project, the most prevalent risk factors for thrombosis include central venous catheters (80%), surgery (43%), systemic steroids (31%), CHD (27%), infection (14%), and cancer (13%). 38 It is estimated that in children with CHD who undergo cardiac surgery the incidence of thrombosis is 11%. Similar to adults, CPB in children is associated with disruption of endothelial surfaces, platelet dysfunction, and inflammation, all of which contribute to disturbances in coagulation. However, unlike adults, the hemostatic system of infants is not fully developed. Levels of major pro-and anticoagulant factors are low at birth and do not reach adult levels until around 6 months of age. Infants also have qualitative deficiencies in several coagulation proteins. Although the mean plasma fibrinogen concentration in infants is comparable to that in adults, the fibrinogen is dysfunctional and exists in fetal form until around 1 year of age. Similarly, key components of the fibrinolytic system also are decreased and dysfunctional. 39 Thrombosis after cardiac surgery is associated with significant morbidity and mortality. Faraoni and colleagues performed a prospective study of 138 infants undergoing cardiac surgery to assess the relationship between intraoperative transfusion of blood products and the occurrence of postoperative thrombosis. 40 They report a 9% incidence of postoperative thrombotic complication. Not unexpectedly, infants who were cyanotic and experienced longer CPB times and deep hypothermic circulatory arrest had a higher incidence of thrombosis. They also received more intraoperative blood products (odds ratio [OR] = 2.23). Additionally, the amount of blood products transfused was associated with increases in TEG (thromboelastography) and ROTEM (rotational thromboelastometry) clotting amplitudes measured at the time of intensive care unit admission, whereas there was no difference in those measures immediately after bypass. Hunt and colleagues studied 133 infants with CHD undergoing cardiac surgery and also found a 9% incidence of postoperative thrombotic events. 41 They also studied perioperative changes in von Willebrand Factor (VWF) and ADAMTS-13. VWF is a large, multimeric glycoprotein that mediates platelet-platelet and platelet-endothelium adhesion. On its release from activated platelets and the endothelium, VWF predominantly exists in the form of large, hyperreactive multimers. The biologic activity of VWF is primarily regulated by ADAMTS-13, a plasma metalloprotease, which specifically degrades VWF into smaller, less thrombotic forms. The study investigators found a significant postoperative increase in VWF activity and concentration and a decrease in ADAMTS-13 activity, which may partly explain the increased thrombosis in post-operative patients with CHD.
Post-CPB blood product transfusion may be optimal when guided by intraoperative point of care coagulation monitoring, although there are no defined algorithms and the threshold values for each intervention are likely to be different and specific for each point of care test. Gautam and colleagues studied the correlation between functional fibrinogen assay of the TEG (FFTEG) and standard laboratory tests for fibrinogen. 42 They prospectively studied 105 children and found functional fibrinogen levels measured by FFTEG consistently measured higher than laboratory measured fibrinogen levels at all time points during cardiac surgery. This positive correlation may help post-CPB management of bleeding in children. In another study, Rizza and colleagues in Italy studied FFTEG, TEG, and standard coagulation assays in children with cyanotic and acyanotic CHD undergoing cardiac surgery. 43 They found that TEG parameters in their 63-patient cohort (38 cyanotic and 25 acyanotic) are similar to the established TEG values in healthy children. Furthermore, cyanotic and acyanotic children did not differ significantly regarding preoperative baseline and intraoperative values on both standard coagulation tests and TEG parameters. They also found functional fibrinogen measured by FFTEG correlated with laboratory measured fibrinogen levels and was the only factor associated with postoperative bleeding. Rajkumar and colleagues in India used Sonoclot point of care testing in a prospective study of postoperative bleeding in 87 children with cyanotic CHD undergoing cardiac surgery. 44 They found that of the 33.9% of children who had excessive postoperative chest tube drainage, Sonoclot glass bead activation time, clot rate, and platelet function had the highest predictive value. Children with cyanotic CHD typically have elevated hematocrits but their platelet counts may be variable. Matter and colleagues in Egypt studied the frequency of thrombocytopenia in pediatric patients with cyanotic CHD and evaluated immature platelet function (IPF) and its role in the pathogenesis of thrombocytopenia. 45 They studied 46 children with cyanotic CHD during cardiology clinic visits and found that 6 patients (13%) were thrombocytopenic and IPF was significantly higher in these children compared with those with a normal platelet count. The investigators suggest that elevated IPF in cyanotic CHD patients with thrombocytopenia may denote peripheral platelet destruction as an underlying mechanism rather than low production.
Adults with CHD have additional considerations for the thromboembolism-bleeding spectrum (Table 1) . Optimum anticoagulation strategies for thromboembolic risk reduction in adults with CHD are not known, mostly because of their heterogeneity and complex clinical profiles. Two review articles nicely summarize the current risk factors, prophylaxis, and treatment of thromboembolism in adults with CHD. 46, 47 The use of blood and blood products is a common practice in pediatric cardiac surgery. However, the transfusion of red blood cells has been shown to be associated with an increase in morbidity. Karimi and colleagues used the Pediatric Health Information System database to study the current variability over the past decade in blood usage among 43 children's hospitals performing pediatric cardiac surgery in the United States. 48 They found that blood transfusion practices have not changed over the past 10 years and that most of the variation occurred in younger patients and in patients of higher STAT complexity categories across all centers. Most important, no changes have occurred in the practice of red blood cell utilization or in the adaption of blood conservation practices for less complex and older age groups in current practice compared with congenital cardiac surgery practice a decade ago. This suggests many institutions should critically look at their blood usage and enforce blood conservation practices as a quality initiative.
Infants undergoing cardiac surgery with CPB often have the bypass circuit primed with both red blood cells and fresh frozen plasma (FFP). Bianchi and colleagues in Italy studied if the administration of FFP after CPB (late FFP group) is superior to FFP in the bypass prime (early FFP group) in terms of postoperative bleeding and total red blood cell transfusion. 49 They conducted a prospective single-center, randomized study in 73 infants weighing less than 10 kg. They found that patients in the late FFP group had greater postoperative blood loss than patients in the early FFP group (33.1 vs 24.1 mL/kg, P = .028) but no difference in transfusions were found. The subgroup of cyanotic CHD patients had comparable results but with greater use of red blood cells in the late FFP group. One animal study by Schmidt and colleagues investigated whether the addition of blood after institution of CPB alters the inflammatory response compared with a blood prime. 50 Using neonatal piglets, they found asanguinous primes released less inflammatory mediators including tumor necrosis factor and interleukin-10, and although the animals spent time with a lower hematocrit they did not have elevated lactate levels at the end of CPB compared with animals who had a blood prime in the CPB circuit. The study investigators conclude that using an asanguinous prime for neonates being cooled to deep hypothermia could be practical, and the later addition of blood reduces inflammation.
Adult and pediatric data demonstrate associations between blood product transfusions and adverse patient outcomes. 51 Thus, efforts to limit bleeding after CPB and minimize blood product exposure are warranted. The use of factor concentrates is increasing in the CHD population undergoing cardiac surgery. These factors do not require cross-matching, may be administered in a small volume, and are readily available, less labor-intensive, and not associated with the same infectious and noninfectious risks as blood product transfusions. Promising factor concentrates include fibrinogen concentrate (RiaSTAP, CSL Behring, Marburg, Germany) and prothrombin complex concentrates (PCC). The specific composition of PCC preparations varies depending on the manufacturer. However, most include Factors II, VII, IX, X and a few contain small amounts of the anticoagulant proteins C, S, and antithrombin. Three-factor PCCs contain low levels of Factor VII and therapeutic levels of Factor II, IX, and X. In contrast, 4-factor PCCs contain therapeutic amounts of all the vitamin K-dependent factors. The majority of PCC formulations contain inactivated factors. Factor Eight Inhibitor Bypassing Activity (FEIBA, Baxter Healthcare, Westlake Village, CA) is the only activated PCC in the United States and contains Factors VIIa and Xa. Guzzetta and Williams provide an excellent review on the current use of factor concentrates in pediatric cardiac surgery, but they conclude that because factor concentrates do not address all of the reasons that patients bleed after CPB, they must be integrated into a comprehensive strategy to achieve hemostasis and limit blood product usage. 51 In order to understand how they are best suited to accomplish these goals, data demonstrating their efficacy, safety, and cost-effectiveness are required.
Adult Congenital Heart Disease
In high-income countries, life expectancy and quality of life for children born with CHD have greatly improved over the past 30 years. The mean age of adults with CHD has increased to 40 years, and the number of adults with CHD over the age of 65 years continues to grow. The numerous advances in the field of CHD has resulted in an epidemiological shift of more children successfully transitioning to productive adult lives, such that there are now more adults living with CHD than there are children with CHD. In many low-and middle-income countries, this survival advantage has not occurred principally because of inadequate facilities for surgical or interventional therapies. 52 The adult CHD population is at risk of developing both the chronic multisystem diseases of adulthood, such as coronary artery disease, diabetes mellitus, and systemic hypertension, and the specific sequelae related to CHD, the most common of which is arrhythmia. It has become increasingly important for practitioners to understand not only the late sequelae of their patients' CHD but also the noncardiac problems that develop in adulthood. A systematic approach to this will help the anesthesiologist formulate a suitable perioperative plan for the adult with CHD. 53 The American Heart Association released a scientific statement on the diagnosis and management of noncardiac complications in adults with CHD. 54 This excellent statement covers some of the organ systems most frequently affected ( Figure 1 ) and provides details on the prevalence, pathogenesis and 47 management of these comorbidities. A stepwise approach to the perioperative assessment and management of adults with CHD is also discussed.
Hepatic dysfunction is common in the adult CHD population. 55 The mechanisms causing hepatic dysfunction are multifactorial, including chronic elevation of central venous pressure, hypoxemia, and increased mesenteric vascular resistance. Volume overload and low cardiac output may lead to both liver congestion, known as congestive hepatopathy, and hepatic ischemia. Additional factors that may lead to hepatic dysfunction include blood transfusions and viral hepatitis. The end stage of this situation is fibrosis, cirrhosis, and even hepatocellular carcinoma. Adachi and colleague studied the impact of liver disorders on the perioperative management of adults with CHD having reoperative cardiac surgery. 56 In their retrospective review of 32 adults with CHD, they found 38% had hepatic dysfunction. Furthermore, those patients with preoperative hepatic dysfunction had longer duration of surgery and anesthesia and required more platelet transfusions. These findings suggest that the prevention and perioperative management of hepatic dysfunction may improve outcomes in adults with CHD undergoing reoperative cardiac surgery. However, how to best detect and diagnose hepatic dysfunction in adults with CHD is not understood. Although liver biopsy is currently considered to be the gold standard approach to the diagnosis of liver fibrosis, the procedure is not without risk. Additionally, sedation or anesthesia is needed. The search for noninvasive techniques to screen for liver disease in the adult CHD population is ongoing. Ultrasound, CT, and MRI have been proposed. Newer techniques such as acoustic radiation force impulse elastography (AFRI) look at liver stiffness. Mebus and colleagues in Germany studied the noninvasive assessment of liver changes in 10 adults with Eisenmenger syndrome. 57 In their small series, abdominal ultrasound using transient elastography to measure liver stiffness could not detect fibrosis or cirrhosis in any affected patient, while AFRI was very reliable. Meanwhile, BuendiaFuentes and colleagues in Spain characterized the frequency of liver disease in 37 adult Fontan patients using multimodality imaging. 58 They found that signs of liver disease were observed in most patients by both hepatic MRI and AFRI but not by ultrasound imaging. Furthermore, increased liver stiffness did not identify specific disease patterns from MRI, supporting the need for multimodality imaging to characterize liver disease in Fontan patients.
Liver disease is an important contributor to morbidity and mortality in patients after Fontan surgery. Wu and colleagues studied the prevalence and predictors of liver disease in adults with Fontan physiology. 59 They recruited 241 subjects from 6 adult congenital heart centers in the United States and reported a median age of 25.8 years, a median time since Fontan surgery of 20.3 years, and more than 94% had at least one abnormal liver-related finding. All hepatic imaging and liver histology was abnormal. Few correlations were identified between degree of histopathologic liver disease and patient characteristics or findings on noninvasive testing. The investigators suggest that further research is needed to identify the Fontan patients at highest risk for significant liver disease. At this time, Evans and colleagues studied a noninvasive composite Fontan hepatic index in 30 adult Fontan patients who underwent cardiac catheterization and liver biopsy. 60 They found that a composite index composed of hepatic ultrasound elastography measurements, MELD scores (Model for End Stage Liver Disease), and time post-Fontan strongly correlated with the total fibrosis score from liver biopsy.
Although medium-term survival following Fontan operations in the modern era has improved dramatically, late cardiovascular and extracardiac morbidity are common and are associated with impaired quality of life and premature late mortality. In their excellent review article, Veldtman and colleagues remind us of the extraordinary adaptions required of the cardiovascular system when the systemic arterial, systemic venous, and pulmonary circulations are placed in series coupled to a single ventricular pump. 61 We are further reminded of the histopathological abnormalities of the vasculature in Fontan patients in a postmortem study of 13 patients by Hays and colleagues. Adults with Fontan circulation, like other patients with CHD, often require noncardiac procedures (NCP) as they age. There is an increased risk of perioperative complications after NCP in patients with CHD and this risk varies by complexity of CHD, type of NCP, and the presence of other comorbidities. Egbe and colleagues compared procedural outcomes after NCPs in adult Fontan patients with outcomes for 2 matched control groups: patients with repaired CHD and biventricular circulation (CHD-BiV) and patients with no heart disease. 63 They found that complications were more common in the Fontan group and baseline cyanosis was the only multivariable risk factor for complications.
Ultimately, many adults with complex CHD may require a heart transplant that may also include a lung or liver transplant at the same time. Marrone and colleagues looked at long-term heart transplant outcomes of children with univentricular hearts at different stages of palliation. 64 They report an overall survival at 1, 10, and 20 years of 73%, 58%, and 49%, respectively. However, many children with univentricular hearts are now palliated to a Fontan circulation and may not require transplant until adulthood. This delays the need for immunosuppression, retransplant, and means there will be a larger donor pool as an adult heart transplant candidate. Matsuda and colleagues from Japan provide a review of heart transplantation for adults with CHD. 65 They note that although early and late outcomes of heart transplantation have been improving for adults with CHD, outcomes and pretransplant management could still be improved. They describe adult Fontan survivors as a particularly vulnerable group, due to univentricular heart failure plus multiple comorbidities, the most significant of which appears to be hepatic dysfunction. Menachem and colleagues provide one of the first descriptive studies of adults with CHD undergoing heart and another organ transplant. 66 In their reported series of 20 consecutive patients, 8 were single ventricles palliated to Fontan circulations, 8 patients required pretransplant inotropes, and 2 required pretransplant mechanical support. Nine patients underwent heart-liver transplant and 3 underwent heart-lung transplant (HLTx). Three patients required postoperative mechanical support. There was a 100% survival at 30 days and 94% survival at 1 year. Adult CHD heart transplant patients require highly specialized, complex, and multidisciplinary health care.
In a review of the current HLTx literature, Pasupneti et al report that the most common indications for HLTx are CHD (35%) followed by pulmonary arterial hypertension (27%). 67 Pulmonary arterial hypertension (PAH) is a wellrecognized complication of adult CHD. However, management is not currently standardized between centers and guidelines are lacking. Tulloh and colleagues in the United Kingdom conducted a survey of physicians managing adults with PAH-CHD. 68 They report that although 97% of respondents have access to a specialist pediatric health center, patients are still being managed in nonspecialist settings. Shared care arrangements are widespread but only 41% have formal shared care protocols. Palliative care services are limited and general cardiologists rarely perform 6-minute walk tests or quality of life assessments. Adults with PAH-CHD are often undertreated with 39% of respondents reporting that less than 25% of these patents were receiving PAH-specific therapies. This is particularly concerning as Schuijt and colleagues from the Netherlands studied serial changes in standard clinical parameters, such as World Health Organization functional classification, 6-minute walk test, oxygen saturation at peak exercise, and echocardiographic right ventricular function in adults with PAH-CHD, and found that serial changes in these parameters have more prognostic value compared with baseline parameters. 69 This emphasizes the importance of screening for serial changes to guide treatment decisions to delay disease progression. Back in the United Kingdom, Price and colleagues recognized that treatment of PAH emergencies can be challenging, and the majority of patients do not live close to specialist pediatric health centers. 70 Based on expert opinion they developed management protocols for the following PAH emergencies: chest pain (including myocardial ischemia), right ventricular failure, arrhythmias, sepsis, hemoptysis (CRASH), as well as considerations relevant to surgery, anesthesia, and pregnancy. Hopefully, they will study and report their findings after these protocols have been implemented to support all physicians who are managing pediatric health emergencies locally.
In 2017, the American Heart Association (AHA) released a scientific statement on the management of pregnancy in patients with complex CHD. 71 For many women with complex CHD, carrying a pregnancy carries a moderate to high risk for both the mother and her fetus. Many such women, however, do not have access to adult CHD tertiary centers with experienced reproductive programs. This AHA statement discusses the assessment and management of women with complex CHD during pregnancy, labor, and in the postpartum period. It addresses specific cardiac complications such as arrhythmias, mechanical valves and anticoagulation, heart failure, cyanosis, as well as specific lesions such as PAH and Fontan physiology. Ladouceur and colleagues in France specifically studied the pregnancy outcomes in women with PAH-CHD. 72 They report 28 pregnancies in 20 women of which 6 patients (33%) experienced severe cardiac events including lower oxygen saturation (79% vs 89%) and heart failure, which required mechanical support in one patient and led to one maternal death (mortality of 5%). Premature delivery was frequent (78%) and 38% of fetuses were small for gestational age. In a similar study of women with CHD palliated with a Fontan circulation, Cauldwell and colleagues report on 124 pregnancies in 50 women. 73 Cardiac complications in pregnancies with a live birth included heart failure (13.5%), arrhythmia (11.3%), and pulmonary embolism (1.9%). Very low baseline maternal oxygen saturations at first obstetric review were associated with miscarriage. All 8 women with saturations less than 85% miscarried compared with 51% of women who had baseline saturations of more than 85%. Maternal and neonatal complications were common: preterm delivery (72%), small for gestational age (90%), and postpartum hemorrhage (43%). There were no maternal deaths. Two additional studies in France report very similar findings for maternal and neonatal outcomes. 74, 75 In an effort to better understand the incidence and predictors of maternal and fetal complications in women with CHD, van Hagen and colleagues examined a worldwide registry of pregnancy and cardiac disease. 76 They report on 2742 pregnancies in women with CHD. Maternal events occurred in 8.45% and fetal events in 23.7%. In multivariable analysis, aortic valve disease was associated with preeclampsia (OR = 2.6), CHD was associated with spontaneous preterm birth (OR = 1.8), and complex CHD was associated with small for gestational age neonates (OR = 2.3). The study investigators conclude that the increased rate of adverse maternal and fetal outcomes in women with CHD should be highlighted during counselling. Roos-Hesselink and colleagues in the Netherlands address this need for pregnancy counselling and highlight all of the issues that should be discussed. 77 For high-risk women with CHD, they suggest care should be centralized in centers with multidisciplinary expertise. The authors also note the large discrepancy in maternal mortality, which is 14 times higher in low-income compared with high-income countries.
Pregnancy appears to be safe after transcatheter pulmonary valve replacement (TCPVR). Kozicka and colleagues from Poland provide what may be the first report of 4 women with CHD who become pregnant after TCPVR. 78 There were no maternal or fetal adverse events. They did not find a significant increase in pulmonary gradient or progression of pulmonary regurgitation. Systolic function and right ventricular end-diastolic volume remained stable and no deterioration in exercise tolerance was observed. There were no infectious complications observed after recommendations for infective endocarditis prevention were followed.
The incidence of infective endocarditis (IE) among adults with CHD remains substantial. There are between 0.9 and 1.3 cases/1000 patient-years as opposed to the non-CHD population, wherein it is between 5 and 7 cases/100 000 patient-years. 79 It is important to identify CHD patients who are at increased risk of developing IE and its complications. While patients with complex CHD are at higher risk of IE, the incidence of IE in simple lesions is still notable. Moore and colleagues in an Australian retrospective study report that IE was most common in complex CHD and ventricular septal defects. 80 There was a predominance of left-sided lesions and prosthetic material was involved in about 50% of cases. Moore et al also report a high mortality related to IE (15%), higher than other reports. Major contributors to death were multiorgan failure and systemic emboli, especially strokes. Remarkably, most of the deaths occurred in patients with simple lesions (bicuspid aortic valve and VSD) with or without prior surgery. In another retrospective database study from the United Kingdom, Tutarel and colleagues report 164 episodes of IE in 144 adults with CHD. 81 Out of these, 43% had a simple, 23% a moderate, and 32% a complex lesion. The IE mortality rate in their cohort was 6.9%. Using the Quebec CHD database, Mylotte and colleagues found a mortality rate from IE of 8.77% in adults with CHD without prosthetic valves. 82 TCPVR is thought to be associated with a higher risk of IE than surgical pulmonary valve replacement (PVR). Lluri and colleagues in California compared 342 patients who underwent PVR including 134 surgically placed valves and 208 TCPVR. 83 Patients undergoing TCPVR were more likely to have had a history of endocarditis than those undergoing surgical PVR (5.3% vs 0.7%). Two surgical PVR and 7 TCPVR patients developed IE with a 4-year freedom from IE of 94% in the surgical group versus 84% in the TCPVR group (P = .13), which suggests that TCPVR is not at a higher risk of IE. The anesthetic considerations for TCPVR are nicely reviewed by Gregory et al. 84 It is well established that adults with CHD are at increased risk of IE, but there are very few studies that look at the knowledge level of patients about IE and IE prophylaxis. Bauer and colleagues in Germany found important knowledge gaps, where 20% to 30% of adults with CHD and a strict recommendation for antibiotic prophylaxis did not possess knowledge of IE and misjudged their risk for IE. 85 Atrial arrhythmias are the most common complication encountered in the growing and aging adult population with CHD. Labombarda et al studied the type and patterns of atrial arrhythmias in a multicenter cohort study of 482 adults with CHD from 12 centers in the United States. 86 They found the most common presenting arrhythmia was intra-atrial re-entrant tachycardia (IART; 61.6%), followed by atrial fibrillation (28.8%) and focal atrial tachycardia (9.5%). The proportion of arrhythmias due to IART increased with complexity of CHD. Atrial fibrillation increased with age to surpass IART as the most common arrhythmia in those older than 50 years of age. A Dutch study by Yang and colleagues investigated the impact of atrial arrhythmias on outcome in adults with CHD. 87 Using the large CONCOR registry they found that patients with atrial arrhythmias were at major risk of heart failure (4-fold increase) and death (2-fold increase) irrespective of age, sex, repair status, and defect severity with the principle cause of death being heart failure in 40% of the patients. Avila and colleagues from Spain studied atrial arrhythmias in 3311 adults with CHD. 88 Overall, 4.6% of patients presented with an atrial arrhythmia with the greatest burden in adults with complex CHD. Independent risk factors for developing atrial arrhythmias included single ventricle physiology, previous intra-cardiac repair, systemic right ventricle, and pulmonary hypertension. Two articles in 2017 nicely review arrhythmias in adults with CHD. 89, 90 The important message throughout all of these arrhythmia articles is that atrial arrhythmias are not a bystander in the natural history of adult CHD, but deserve careful diagnosis, monitoring, and management. Arrhythmias are a frequent cause of sudden cardiac death (SCD) in adults with CHD. An Australian study by Moore et al found a SCD incidence of 0.4 deaths/1000 patient-years, with an increasing incidence with complexity of CHD. 91 The highest risk category was Eisenmenger syndrome. Moderate risk lesions included transposition of the great arteries (atrial switch surgery) and Fontan circulations. They observed a high prevalence of atrial arrhythmias (43%) and QRS prolongation (mean 132 ms) in their SCD cases. Pundi and colleagues looked specifically at SCD and late arrhythmias after the Fontan operation in a single-center retrospective study in the United States. 92 They found an overall 10-, 20-, and 30-year freedom from arrhythmias of 71%, 42%, and 24%, respectively. Predictors of late arrhythmias included an atriopulmonary Fontan, age at operation (>16 years), or atrial arrhythmias postoperatively. During follow-up, 52 of 1052 patients (5%) had SCD; 8 patients died suddenly within 30 days and the remaining 3 had an average time to SCD of 6.9 ± 6.7 years. Arrhythmias were documented in 65% of patients prior to SCD. SCD may be prevented by implantable cardioverterdefibrillator (ICD) placement, but patient stratification remains problematic. Vehmeijer and colleagues looked at the discriminative abilities of the 2014 Consensus Statement on Arrhythmias in Adult CHD patients and the 2015 European Society of Cardiology Guidelines specified recommendations for ICD placement in adults with CHD. 93 Of 25 790 adult CHD patients in an international multicenter registry, a minority of SCD cases had an ICD recommendation according to these guidelines, whereas the majority of SCD victims remained unrecognized. With an area under the curve of 0.6 to 0.7, the discriminative ability of both guidelines was mediocre. Critical clinical reasoning when deciding on ICD implantation in adult CHD patients, therefore, remains vital. There is a nice review of pacemakers, ICD, and cardiac resynchronization therapy devices in adults with CHD by Cecchin and Halpern. 94 Intraoperative ablation offers an alternative for adults with CHD and atrial arrhythmias who are requiring concomitant surgical intervention. Giamberti and colleagues from Italy report their experience with 80 such patients. 95 Freedom from arrhythmia recurrence was 75% after 6 years of follow-up. Long-term recurrence of arrhythmia in these patients was strongly correlated to preoperative arrhythmia duration.
Another specific group of patients thought to be prone to SCD are patients who have undergone the arterial switch operation (ASO). Van Wijk and colleagues in the Netherlands performed a systematic literature search and identified 52 studies for data analysis. 96 Of the 8798 survivors with follow-up, 27 patients died more than 5 years post-ASO (0.3%). Of these patients, 10 were known to have relevant residual lesions. Five late deaths were sudden, possibly from arrhythmia.
In adults with CHD, acquired cardiac conditions, such as ischemic cerebrovascular events and coronary artery disease (CAD), are of increasing importance. 97 Bokma and colleagues studied factors associated with CAD and stroke in adults with CHD. 98 They performed a multicenter case-control study using data from the CONCOR registry in the Netherlands. Of 6904 adult CHD patients, a total of 55 cases with CAD (80% male, mean age 55 years) and 56 cases with stroke (46% male, mean age 47 years) were studied. Two studies compared outcomes for adults with CHD undergoing cardiac surgery to a control group of adults undergoing cardiac surgery for acquired cardiac conditions, such as coronary artery bypass grafting. 99, 100 Karangelis and colleagues found in the adult CHD group that in hospital mortality was 0.7% compared with no deaths in the control group, and 58% of adult CHD patients had significantly higher perioperative morbidity with arrhythmias (26%), bleeding (3%), prolonged ventilation (11%), and renal replacement therapy (1.5%). In the adult control group, 32% developed perioperative complications (p = .003) with arrhythmias (9.8%), bleeding (2.5%), prolonged ventilation (4.3%), and renal replacement therapy (2.5%). Adult CHD patients had longer CPB times, and longer hospital stays. In the second study by Nasr and colleagues, adults with CHD had higher incidences of in-hospital mortality (2.6% vs 1.8%) and complication rates, including neurologic complications (2.6 vs 0.9%), thromboembolic complications (3.9 vs 1.4%), arrhythmias (51.6 vs 29.8%), hepatic failure (4.44 vs 2.03%) and sepsis (7.24 vs 4.61%) (all p<0.001). Both of these studies suggest that recognition and treatment of comorbidities in adults with CHD undergoing cardiac surgery may provide an opportunity to improve perioperative outcomes in this growing patient population.
Conclusion
The study of CHD continues to grow rapidly as more children survive to adulthood. There is still much to be discovered with many aspects of the care of CHD patients including the impact of anesthetic neurotoxicity, neurodevelopmental outcomes, and the adult CHD population. It is encouraging that there is a continued growth in high-quality studies in the CHD population, the most recent of which we have reviewed in this article.
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